Investors Alerted to Class Actions against Autodesk (ADSK) and Marinus Pharmaceuticals (MRNS)

New York, June 14, 2024 - Notable shareholder rights advocates at Bragar Eagel & Squire, P.C. are reaching out to investors to remind them that class action lawsuits are now underway concerning shareholders of two prominent companies, Autodesk, Inc. ADSK and Marinus Pharmaceuticals, Inc. MRNS. The lawsuits pertain to allegations of statutory violations by the respective company's management, potentially affecting the rights and financial interests of their stockholders.

About Autodesk, Inc.

Autodesk, Inc. ADSK, a highly regarded entity in the software industry, crafts specialized products and services that cater to the needs of diverse sectors, including architecture, engineering, construction, manufacturing, media, education, and entertainment. With its base of operations in San Rafael, California, Autodesk's influence spans the globe, setting the standard in design and engineering software.

About Marinus Pharmaceuticals, Inc.

Concentrating on the sphere of rare seizure disorders, Marinus Pharmaceuticals, Inc. MRNS is on the vanguard of developing groundbreaking treatments. As a clinical-stage pharmaceutical company, Marinus stands out for its commitment to bringing innovative therapy options to those in need, operating from its headquarters in Radnor, Pennsylvania.

Investors currently holding shares of ADSK or MRNS are encouraged by the law firm to stay informed and vigilant as the class action suits progress. Participation in such legal proceedings may help to secure their rights and potentially recover losses tied to any proved misdeeds by the companies' management teams.

Investment, Lawsuit, Stocks